MARKED HYPERFERRITINEMIA (SERUM FERRITIN>10000?G/L). A POOR PROGNOSIS FACTOR.
(Abstract release date: 05/19/16)
EHA Library. Remacha A. 06/09/16; 135040; PB2140
Dr. Angel F Remacha
Contributions
Contributions
Abstract
Abstract: PB2140
Type: Publication Only
Background
Iron overload is a poor prognosis factor in patients with myelodysplasic syndromes or patients undergoing hematopoietic stem cell transplantation (HSCT) when considering a serum ferritin (Ft) of 1000 µg/l as a threshold. Marked hyperferritinemia (MHFT) is a hallmark of hemophagocytic syndromes and is a diagnostic criterion of the hemophagocytic lymphohistiocytosis.
Aims
The characteristics of patients with MHFT (Ft>10000µg/l) were studied.
Methods
Cases with hyperferritinemia (> 1000 µg/l) and the characteristics of the patients with MHFT (Ft> 10000 µg/l) were studied for a year. Serum Ft was evaluated using an Architect c.i. 16200 (Abbott Diagnostics).
Results
A total of 1056 samples presented Ft ≥ 1000 µg/l, 40 of which showed a MHFT(3.8%) in 25 patients.Of these, 12 died (48%) between 2 and 67 days after the determination, including: 4 non hematological neoplasias with metastasis; 3 with infection after HSCT; 2 with hemophagocytic syndrome associated with chronic myelomonocytic leukemia and diffuse large B-cell lymphoma (DLBCL); 1 respiratory infection during T – cell lymphoma treatment; 1 acute myeloid leukemia in pancytopenia postchemotherapy and 1 chronic lymphatic leukemia that evolved into a Hodgkin’s lymphoma.Of the 13 who survived, 7 presented infection while undergoing HSCT (viral infection caused by CMV in three cases, type A influenza virus in 2 and 1 viral encephalitis; 1 fungal infection (aspergillus) and 2 bacterial sepsis (pseudomonas). The six remaining cases showed 2 hepatopathy (1 hepatic cirrhosis with MRSA sepsis and 1 on the onset of autoimmune hepatitis); 2 presented MHFT during chemotherapy (1 acute myeloid leukemia and 1 for DLBCL plus aspergillus infection); 1 was a myelodysplastic undergoing HSCT with severe previous transfusional hemosiderosis; and, finally, 1 with pancytopenia in a kidney transplanted patient.
Conclusion
MHFT is a poor prognosis factor and half of the patients died after a few days. In those who survived, MHFT appeared during infection, especially viral infections, in patients undergoing HSCT or receiving chemotherapy. In this regard, MHFT is a useful sign of viral infection. Further studies are warranted to confirm the clinical value of MHFT.
Session topic: E-poster
Keyword(s): Ferritin, Hematopoietic cell transplantation, Infection, Iron overload
Type: Publication Only
Background
Iron overload is a poor prognosis factor in patients with myelodysplasic syndromes or patients undergoing hematopoietic stem cell transplantation (HSCT) when considering a serum ferritin (Ft) of 1000 µg/l as a threshold. Marked hyperferritinemia (MHFT) is a hallmark of hemophagocytic syndromes and is a diagnostic criterion of the hemophagocytic lymphohistiocytosis.
Aims
The characteristics of patients with MHFT (Ft>10000µg/l) were studied.
Methods
Cases with hyperferritinemia (> 1000 µg/l) and the characteristics of the patients with MHFT (Ft> 10000 µg/l) were studied for a year. Serum Ft was evaluated using an Architect c.i. 16200 (Abbott Diagnostics).
Results
A total of 1056 samples presented Ft ≥ 1000 µg/l, 40 of which showed a MHFT(3.8%) in 25 patients.Of these, 12 died (48%) between 2 and 67 days after the determination, including: 4 non hematological neoplasias with metastasis; 3 with infection after HSCT; 2 with hemophagocytic syndrome associated with chronic myelomonocytic leukemia and diffuse large B-cell lymphoma (DLBCL); 1 respiratory infection during T – cell lymphoma treatment; 1 acute myeloid leukemia in pancytopenia postchemotherapy and 1 chronic lymphatic leukemia that evolved into a Hodgkin’s lymphoma.Of the 13 who survived, 7 presented infection while undergoing HSCT (viral infection caused by CMV in three cases, type A influenza virus in 2 and 1 viral encephalitis; 1 fungal infection (aspergillus) and 2 bacterial sepsis (pseudomonas). The six remaining cases showed 2 hepatopathy (1 hepatic cirrhosis with MRSA sepsis and 1 on the onset of autoimmune hepatitis); 2 presented MHFT during chemotherapy (1 acute myeloid leukemia and 1 for DLBCL plus aspergillus infection); 1 was a myelodysplastic undergoing HSCT with severe previous transfusional hemosiderosis; and, finally, 1 with pancytopenia in a kidney transplanted patient.
Conclusion
MHFT is a poor prognosis factor and half of the patients died after a few days. In those who survived, MHFT appeared during infection, especially viral infections, in patients undergoing HSCT or receiving chemotherapy. In this regard, MHFT is a useful sign of viral infection. Further studies are warranted to confirm the clinical value of MHFT.
Session topic: E-poster
Keyword(s): Ferritin, Hematopoietic cell transplantation, Infection, Iron overload
Abstract: PB2140
Type: Publication Only
Background
Iron overload is a poor prognosis factor in patients with myelodysplasic syndromes or patients undergoing hematopoietic stem cell transplantation (HSCT) when considering a serum ferritin (Ft) of 1000 µg/l as a threshold. Marked hyperferritinemia (MHFT) is a hallmark of hemophagocytic syndromes and is a diagnostic criterion of the hemophagocytic lymphohistiocytosis.
Aims
The characteristics of patients with MHFT (Ft>10000µg/l) were studied.
Methods
Cases with hyperferritinemia (> 1000 µg/l) and the characteristics of the patients with MHFT (Ft> 10000 µg/l) were studied for a year. Serum Ft was evaluated using an Architect c.i. 16200 (Abbott Diagnostics).
Results
A total of 1056 samples presented Ft ≥ 1000 µg/l, 40 of which showed a MHFT(3.8%) in 25 patients.Of these, 12 died (48%) between 2 and 67 days after the determination, including: 4 non hematological neoplasias with metastasis; 3 with infection after HSCT; 2 with hemophagocytic syndrome associated with chronic myelomonocytic leukemia and diffuse large B-cell lymphoma (DLBCL); 1 respiratory infection during T – cell lymphoma treatment; 1 acute myeloid leukemia in pancytopenia postchemotherapy and 1 chronic lymphatic leukemia that evolved into a Hodgkin’s lymphoma.Of the 13 who survived, 7 presented infection while undergoing HSCT (viral infection caused by CMV in three cases, type A influenza virus in 2 and 1 viral encephalitis; 1 fungal infection (aspergillus) and 2 bacterial sepsis (pseudomonas). The six remaining cases showed 2 hepatopathy (1 hepatic cirrhosis with MRSA sepsis and 1 on the onset of autoimmune hepatitis); 2 presented MHFT during chemotherapy (1 acute myeloid leukemia and 1 for DLBCL plus aspergillus infection); 1 was a myelodysplastic undergoing HSCT with severe previous transfusional hemosiderosis; and, finally, 1 with pancytopenia in a kidney transplanted patient.
Conclusion
MHFT is a poor prognosis factor and half of the patients died after a few days. In those who survived, MHFT appeared during infection, especially viral infections, in patients undergoing HSCT or receiving chemotherapy. In this regard, MHFT is a useful sign of viral infection. Further studies are warranted to confirm the clinical value of MHFT.
Session topic: E-poster
Keyword(s): Ferritin, Hematopoietic cell transplantation, Infection, Iron overload
Type: Publication Only
Background
Iron overload is a poor prognosis factor in patients with myelodysplasic syndromes or patients undergoing hematopoietic stem cell transplantation (HSCT) when considering a serum ferritin (Ft) of 1000 µg/l as a threshold. Marked hyperferritinemia (MHFT) is a hallmark of hemophagocytic syndromes and is a diagnostic criterion of the hemophagocytic lymphohistiocytosis.
Aims
The characteristics of patients with MHFT (Ft>10000µg/l) were studied.
Methods
Cases with hyperferritinemia (> 1000 µg/l) and the characteristics of the patients with MHFT (Ft> 10000 µg/l) were studied for a year. Serum Ft was evaluated using an Architect c.i. 16200 (Abbott Diagnostics).
Results
A total of 1056 samples presented Ft ≥ 1000 µg/l, 40 of which showed a MHFT(3.8%) in 25 patients.Of these, 12 died (48%) between 2 and 67 days after the determination, including: 4 non hematological neoplasias with metastasis; 3 with infection after HSCT; 2 with hemophagocytic syndrome associated with chronic myelomonocytic leukemia and diffuse large B-cell lymphoma (DLBCL); 1 respiratory infection during T – cell lymphoma treatment; 1 acute myeloid leukemia in pancytopenia postchemotherapy and 1 chronic lymphatic leukemia that evolved into a Hodgkin’s lymphoma.Of the 13 who survived, 7 presented infection while undergoing HSCT (viral infection caused by CMV in three cases, type A influenza virus in 2 and 1 viral encephalitis; 1 fungal infection (aspergillus) and 2 bacterial sepsis (pseudomonas). The six remaining cases showed 2 hepatopathy (1 hepatic cirrhosis with MRSA sepsis and 1 on the onset of autoimmune hepatitis); 2 presented MHFT during chemotherapy (1 acute myeloid leukemia and 1 for DLBCL plus aspergillus infection); 1 was a myelodysplastic undergoing HSCT with severe previous transfusional hemosiderosis; and, finally, 1 with pancytopenia in a kidney transplanted patient.
Conclusion
MHFT is a poor prognosis factor and half of the patients died after a few days. In those who survived, MHFT appeared during infection, especially viral infections, in patients undergoing HSCT or receiving chemotherapy. In this regard, MHFT is a useful sign of viral infection. Further studies are warranted to confirm the clinical value of MHFT.
Session topic: E-poster
Keyword(s): Ferritin, Hematopoietic cell transplantation, Infection, Iron overload
{{ help_message }}
{{filter}}